Josép María Ribera Santasusana-rekin lankidetzan egindako argitalpenak (16)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

    HemaSphere

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Blood Advances, Vol. 6, Núm. 18, pp. 5395-5402

2021

  1. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 35, Núm. 12, pp. 3585-3588

2020

  1. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics

    Blood Cancer Journal, Vol. 10, Núm. 4

2019

  1. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

    Genes Chromosomes and Cancer, Vol. 58, Núm. 11, pp. 815-819

2018

  1. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

2017

  1. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

    Annals of hematology, Vol. 96, Núm. 7, pp. 1069-1075

  2. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia

    British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265

2015

  1. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

    Cancer, Vol. 121, Núm. 21, pp. 3809-3817

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

2011

  1. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941

2008

  1. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival

    Journal of Clinical Oncology, Vol. 26, Núm. 35, pp. 5775-5782

2005

  1. Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry

    Haematologica, Vol. 90, Núm. 10, pp. 1365-1372